There are no direct clinical comparison outcome studies of HDR, permanent seeds, or SBRT. Because ADT has not been shown to enhance disease control with HDR prostate brachytherapy and ADT is usually not required for downsizing of prostate volume with HDR brachytherapy, it can usually be omitted for favorable risk group cases. Most centers in the United States have used HDR monotherapy click here to treat low- and intermediate-risk group disease whereas those in Asia and Europe treat

patients in all risk groups. HDR brachytherapy can be used to deliver the dose to a definable margin around the prostate and into the seminal vesicles; thus it effectively treats patients with local

extension beyond the prostate. Buparlisib ic50 Whether higher risk group patients should have HDR monotherapy or HDR combined therapy with EBRT remains to be determined. There is no consensus on the optimal dose and fractionation schedule for HDR brachytherapy. The longest followup for outcomes is with moderate-hypofractionation (4–9 fractions), but excellent results are being reported with ultra-hypofractionation (1–3 fractions). The emergence of ultra-hypofractionation with only 1–2 treatments makes HDR logistically comparable to seed implant and adds a high degree of dosimetry control and accuracy in brachytherapy. There are two simulation and dosimetry methods (TRUS and CT). The advantages of TRUS are its use of real-time imaging and interactive dosimetry whereas CT dosimetry provides the clearest images of catheters and the relationship of the implant to adjacent organs. The TRUS approach is most time efficient. Regardless of the imaging modality and treatment planning system, HDR monotherapy is an excellent treatment modality for the management of prostate cancer. “
“The corrected mafosfamide authorship is: Dorin A. Todor, Mitchell S. Anscher, Jeremy D. Karlin, Michael P. Hagan Department of Radiation Oncology,

Virginia Commonwealth University, Richmond, VA The authors apologize for any inconvenience caused. “
“Breast-conserving therapy (BCT) represents one of the seminal treatment breakthroughs in the management of breast cancer. With more than 20-year followup, multiple randomized trials have found comparable outcomes between BCT and mastectomy, allowing women to choose to preserve their breast without compromising their ability to be cured of their cancer [1], [2] and [3]. Beyond simply preserving the breast, BCT has been associated with improved quality of life, including social functioning, body image, and physical functioning, compared with mastectomy (4).